1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Writedowns and US decline hit Dr Reddy's third quarter

 
• By Anju Ghangurde

Dr Reddy’s Laboratories reported a loss of Rs5.2 billion ($112 million) for the third quarter ended December 31st, 2009, hit by writedowns in its German business, Betapharm, and a decline in revenues from the US. Total revenues for the period fell by 6% to Rs17.3 billion.

Dr Reddy’s Laboratories reported a loss of Rs5.2 billion ($112 million) for the third quarter ended December 31st, 2009, hit by writedowns in its German business, Betapharm, and a decline in revenues from the US. Total revenues for the period fell by 6% to Rs17.3 billion.

The company said that prices in the German generics market fell further as a result of a higher pace of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.